{"id":44206,"date":"2024-05-13T22:33:12","date_gmt":"2024-05-13T22:33:12","guid":{"rendered":"https:\/\/www.fomatmedical.com\/?p=44206"},"modified":"2026-04-19T11:18:02","modified_gmt":"2026-04-19T18:18:02","slug":"mash-fibrosis-clinical-trials","status":"publish","type":"post","link":"https:\/\/fomatmedical.com\/es\/blogs-updates\/mash-fibrosis-clinical-trials\/","title":{"rendered":"La lucha oculta: c\u00f3mo la fibrosis est\u00e1 redefiniendo el futuro del tratamiento de la MASH (esteatohepatitis asociada a disfunci\u00f3n metab\u00f3lica)"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"44206\" class=\"elementor elementor-44206\" wpc-filter-elementor-widget=\"1\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-bd81399 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"bd81399\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-54b1453\" data-id=\"54b1453\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-00af0b6 elementor-widget elementor-widget-text-editor\" data-id=\"00af0b6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">MASH fibrosis clinical trials are redefining how we approach liver disease. Imagine your body as a bustling city where everything works seamlessly, maintaining the delicate balance of health. <span data-contrast=\"auto\">Now, think of non-alcoholic steatohepatitis <a href=\"https:\/\/www.fomatmedical.com\/mash-clinical-trials\/\">(NASH) or Metabolic dysfunction-associated steatohepatitis (MASH<\/a>) as an insidious construction project gone wrong inside this city, gradually laying down unwanted infrastructure\u2014fibrosis\u2014within the liver. Over time, without intervention, this can escalate to severe stages of liver fibrosis and even cirrhosis, silently escalating to life-threatening complications. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) or<\/span>Metabolic dysfunction-associated steatohepatitis (MASH) <span data-contrast=\"auto\">are common conditions with a rising burden<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34416976\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"auto\">1<\/span><\/a><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;335557856&quot;:16777215,&quot;335559738&quot;:240}\">\u00a0<\/span><\/p><p><span data-contrast=\"auto\">Experts estimate about 24% of U.S. adults have NAFLD and about 1.5% to 6.5% of U.S. adults have NASH\/MASH <\/span><a href=\"https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts#:~:text=Only%20a%20small%20number%20of,of%20U.S.%20adults%20have%20NASH.\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"auto\">2<\/span><\/a><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;335557856&quot;:16777215,&quot;335559738&quot;:210,&quot;335559739&quot;:210}\">\u00a0<\/span><\/p><p><span class=\"TextRun SCXW226795230 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW226795230 BCX0\">Millions of people are currently living in this reality, alongside the growing global rates of obesity and diabetes. As a result, MASH is not merely a medical condition but a substantial public health issue.<\/span> <span class=\"NormalTextRun SCXW226795230 BCX0\">Understanding<\/span><span class=\"NormalTextRun SCXW226795230 BCX0\"> fibrosis\u2014its progression from MASH and its detection\u2014has therefore become central to contemporary clinical trials. <\/span><\/span><span class=\"EOP SCXW226795230 BCX0\" data-ccp-props=\"{&quot;335557856&quot;:16777215,&quot;335559738&quot;:240}\">\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-aa712d5 elementor-widget elementor-widget-spacer\" data-id=\"aa712d5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b9a625e elementor-widget elementor-widget-heading\" data-id=\"b9a625e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">MASH Fibrosis in Clinical Trials: Progression and Impact\n\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-467382a elementor-widget elementor-widget-text-editor\" data-id=\"467382a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>NASH\/MASH is the aggressive form of non-alcoholic fatty liver disease (NAFLD), characterized by liver inflammation and damage caused by fat buildup in the liver. This condition can progress to fibrosis, which is the formation of excessive connective tissue in the liver as a result of the chronic injury. Without intervention, fibrosis may advance to cirrhosis <a href=\"https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts#:~:text=NASH%20is%20the%20form%20of,is%20scarred%20and%20permanently%20damaged.\" target=\"_blank\" rel=\"noopener\"><sup>3<\/sup><\/a> and liver failure. Also Cirrosis can lead into liver cancer ( Hepatocellular carcinoma)<a href=\"https:\/\/www.cancer.gov\/types\/liver\" target=\"_blank\" rel=\"noopener\"><sup>4<\/sup><\/a>.<\/p><p>The progression from NASH\/MASH to fibrosis and beyond is a critical concern because it signifies a transition from a potentially reversible condition to a permanent and life-threatening state. As such, NASH\/MASH clinical trials often focus on therapies that can halt or reverse this progression.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a86c3ba elementor-widget elementor-widget-spacer\" data-id=\"a86c3ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3af96ea elementor-widget elementor-widget-heading\" data-id=\"3af96ea\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Why Fibrosis Is a Key Player in NASH\/MASH Trials <\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-410a9dd elementor-widget elementor-widget-text-editor\" data-id=\"410a9dd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ol><li>As an Indicator of Disease Progression: The degree of fibrosis in the liver is a strong predictor of future health outcomes in NNASH\/ MASH.\u00a0It helps stratify patients by risk<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33198092\/\" target=\"_blank\" rel=\"noopener\"><sup>5<\/sup><\/a>, tailoring treatments to those who need them most urgently<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10696384\/\" target=\"_blank\" rel=\"noopener\"><sup>6<\/sup><\/a>.<br \/><br \/><\/li><li>As a Measure of Treatment Success: In the world of NASH\/ MASH trials, the effectiveness of a treatment is often measured by its ability to halt or reverse fibrosis <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28521870\/\" target=\"_blank\" rel=\"noopener\"><sup>7<\/sup><\/a>. <br \/><br \/><\/li><li>As a Target for Therapy: Current research is bustling with activity, focusing on therapies that directly target the processes contributing to fibrosis. Understanding and interrupting these pathways could be key to stopping NASH\/ MASH\u00a0\u00a0in its tracks.<\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-953386f elementor-widget elementor-widget-image\" data-id=\"953386f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"624\" height=\"351\" src=\"https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture3.webp\" class=\"attachment-large size-large wp-image-86620\" alt=\"|\" srcset=\"https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture3.webp 624w, https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture3-300x169.webp 300w, https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture3-18x10.webp 18w\" sizes=\"(max-width: 624px) 100vw, 624px\" title=\"|\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d4773c1 elementor-widget elementor-widget-heading\" data-id=\"d4773c1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">FibroScan in NASH\/MASH Clinical Trials  <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3653669 elementor-widget elementor-widget-text-editor\" data-id=\"3653669\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>FibroScan, or transient elastography, has become a cornerstone in the evaluation of liver fibrosis in NASH patients<a href=\"https:\/\/www.medpace.com\/wp-content\/uploads\/2023\/03\/Article-Exploring-the-Complexities-of-NASH-Clinical-Trials.pdf\" target=\"_blank\" rel=\"noopener\"><sup>8<\/sup><\/a>. This non-invasive tool measures liver stiffness, which correlates with the degree of fibrosis.\u00a0<\/p><p>The advantages of using FibroScan in clinical trials include:\u00a0<\/p><ul><li>Non-invasiveness: Unlike liver biopsies, FibroScan is non-invasive and can be performed repeatedly without risk to the patient<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36599683\/#:~:text=Objective:%20A%20simple%20combined%20score,-alcoholic%20steatohepatitis%20(NASH).\" target=\"_blank\" rel=\"noopener\"><sup>9<\/sup><\/a>. This feature is particularly beneficial in clinical trials where frequent monitoring is necessary.<\/li><li>Repeatability: The ability to perform repeated assessments without patient discomfort allows for dynamic monitoring of liver stiffness during clinical trials, providing real-time insights into the therapeutic effects of tested drugs.<\/li><li>Cost-effectiveness and Efficiency: FibroScan is more cost-effective compared to liver biopsy<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10289790\/\" target=\"_blank\" rel=\"noopener\"><sup>10<\/sup><\/a> and can be conducted quickly<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35090390\/\" target=\"_blank\" rel=\"noopener\"><sup>11<\/sup><\/a>, making it ideal for large-scale screenings in clinical trials.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b83f8e0 elementor-widget elementor-widget-spacer\" data-id=\"b83f8e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8273449 elementor-widget elementor-widget-heading\" data-id=\"8273449\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Challenges and Considerations  <\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9c6454b elementor-widget elementor-widget-text-editor\" data-id=\"9c6454b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>While FibroScan offers significant benefits, it also comes with limitations<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7047178\/\" target=\"_blank\" rel=\"noopener\"><sup>12<\/sup><\/a>. Factors such as obesity and the presence of extrahepatic cholestasis can affect the accuracy of liver stiffness measurements<a href=\"https:\/\/journals.lww.com\/ajg\/fulltext\/2020\/10001\/s3264_the_accuracy_of_fibroscan__a_real_world.3262.aspx#:~:text=Patients%20with%20a%20normal%20BMI,0.699,%20P%20=%200.017).\" target=\"_blank\" rel=\"noopener\"><sup>13<\/sup><\/a>. Furthermore, FibroScan does not differentiate between inflammation and fibrosis, which can sometimes lead to misinterpretations of liver stiffness readings.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-272a463 elementor-widget elementor-widget-image\" data-id=\"272a463\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"624\" height=\"356\" src=\"https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture4-1dd.webp\" class=\"attachment-full size-full wp-image-86616\" alt=\"Future of MASH fibrosis monitoring in clinical trials \u2014 researchers analyzing liver data in advanced medical lab\" srcset=\"https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture4-1dd.webp 624w, https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture4-1dd-300x171.webp 300w, https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture4-1dd-18x10.webp 18w\" sizes=\"(max-width: 624px) 100vw, 624px\" title=\"|\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a962fb2 elementor-widget elementor-widget-heading\" data-id=\"a962fb2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Looking Ahead: The Future of Fibrosis Monitoring in NASH\/MASH<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-21f7ab2 elementor-widget elementor-widget-text-editor\" data-id=\"21f7ab2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The medical community is optimistic about refining FibroScan technology and developing new methods to assess liver fibrosis. Imagine biomarkers precise enough to distinguish between mere inflammation and the more sinister fibrosis, or treatments so targeted they can halt fibrosis without side effects.<\/p><p>As we forge ahead, the relentless pace of research and technological innovation heralds a new dawn in combating NASH\/MASH. Each clinical trial we conduct and every breakthrough we achieve in understanding fibrosis bring us steps closer to transforming a once daunting diagnosis into a treatable condition.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5840217 elementor-widget elementor-widget-image\" data-id=\"5840217\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"624\" height=\"351\" src=\"https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture5.webp\" class=\"attachment-full size-full wp-image-86615\" alt=\"MASH fibrosis clinical trials \u2014 doctor holding patient hand with FibroScan device used in liver assessment\" srcset=\"https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture5.webp 624w, https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture5-300x169.webp 300w, https:\/\/fomatmedical.com\/wp-content\/uploads\/2024\/05\/Picture5-18x10.webp 18w\" sizes=\"(max-width: 624px) 100vw, 624px\" title=\"|\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d7284f2 elementor-widget elementor-widget-text-editor\" data-id=\"d7284f2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>At FOMAT Medical Research, our ongoing NASH\/MASH studies are at the forefront of this fight, seeking to unlock new possibilities for prevention, treatment, and recovery. Participating in our studies not only contributes to crucial scientific progress but also lights the path to a healthier future for countless individuals affected by NASH\/MASH.<\/p><p><strong>If you&#8217;re ready to take part in this pivotal research and explore the opportunities our studies offer, we invite you to click below to request more information from our dedicated study team. Join us in this silent battle against NASH\/MASH and become a beacon of hope in advancing medical science.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-418a837 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"418a837\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-62343e8 elementor-widget elementor-widget-text-editor\" data-id=\"62343e8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-size: 8pt;\"><strong><u>References: <\/u><\/strong><\/span><\/p><ol><li><span style=\"font-size: 8pt;\">Buzzetti, E., Pinzani, M., &amp; Tsochatzis, E. A. (2021). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism: Clinical and Experimental, 65*(8), 1038-1048. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34416976\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/34416976\/<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">National Institute of Diabetes and Digestive and Kidney Diseases. (2021). *Definition &amp; facts for NAFLD &amp; NASH.* <a href=\"https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts#:~:text=Only%20a%20small%20number%20of,of%20U.S.%20adults%20have%20NASH\" target=\"_blank\" rel=\"noopener\">https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts#:~:text=Only%20a%20small%20number%20of,of%20U.S.%20adults%20have%20NASH<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">National Institute of Diabetes and Digestive and Kidney Diseases. (2021). *Definition &amp; facts for NAFLD &amp; NASH.* <a href=\"https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts#:~:text=NASH%20is%20the%20form%20of,is%20scarred%20and%20permanently%20damaged\" target=\"_blank\" rel=\"noopener\">https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts#:~:text=NASH%20is%20the%20form%20of,is%20scarred%20and%20permanently%20damaged<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">National Cancer Institute. (n.d.). *Types of liver cancer.* <a href=\"https:\/\/www.cancer.gov\/types\/liver\" target=\"_blank\" rel=\"noopener\">https:\/\/www.cancer.gov\/types\/liver<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">Paik, J. M., Henry, L., &amp; Younossi, Z. M. (2020). The growing burden of nonalcoholic fatty liver disease in the USA: Its contribution to the rising burden of chronic liver disease. *Hepatology International, 15*(1), 132-139. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33198092\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33198092\/<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">Cioni, G., Costa, A., &amp; Ferraiolo, M. (2024). The Role of Ultrasound in the Diagnosis of Non-Alcoholic Fatty Liver Disease. *Diagnostics, 14*(10), 1983. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10696384\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10696384\/<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">Loomba, R., &amp; Adams, L. A. (2017). Advances in non-invasive assessment of hepatic fibrosis. *Gut, 66*(11), 1958-1967. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28521870\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/28521870\/<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">(2023). *Exploring the Complexities of NASH Clinical Trials.* <a href=\"https:\/\/www.medpace.com\/wp-content\/uploads\/2023\/03\/Article-Exploring-the-Complexities-of-NASH-Clinical-Trials.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.medpace.com\/wp-content\/uploads\/2023\/03\/Article-Exploring-the-Complexities-of-NASH-Clinical-Trials.pdf<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">Wijarnpreecha, K., Ahmed, A., &amp; Kim, D. (2023). A simple combined score of fibrosis-4 index and NAFLD fibrosis score for assessing advanced fibrosis in non-alcoholic steatohepatitis (NASH). *Alimentary Pharmacology &amp; Therapeutics, 57*(4), 457-463. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36599683\/#:~:text=Objective:%20A%20simple%20combined%20score,-alcoholic%20steatohepatitis%20(NASH\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36599683\/#:~:text=Objective:%20A%20simple%20combined%20score,-alcoholic%20steatohepatitis%20(NASH<\/a>)<\/span><\/li><li><span style=\"font-size: 8pt;\">O\u2019Neil, A. S., Jennings, A. K., Reeve, M. L., Stewart, J. D., Brown, A. G., Smith, C. J., &amp; Cropley, R. (2023). *Sex differences in liver transplantation for NASH.* <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10289790\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10289790\/<\/a><\/span><\/li><li><span style=\"font-size: 8pt;\">Powell, E. E., Wong, V. W. S., Rinella, M. (2021). Non-alcoholic fatty liver disease. *The Lancet, 397*(10290), 2212-2224. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35090390\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35090390\/<\/a><\/span><\/li><\/ol><ol start=\"12\"><li><span style=\"font-size: 8pt;\">Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., &#8230; &amp; Bugianesi, E. (2020). Global burden of NAFLD and NASH: trends, predictions, risk factors, and prevention. *Nature Reviews Gastroenterology &amp; Hepatology, 16*(1), 20-29. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7047178\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7047178\/<\/a><\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Los ensayos cl\u00ednicos sobre la fibrosis MASH est\u00e1n redefiniendo la forma en que abordamos las enfermedades hep\u00e1ticas. Imagina tu cuerpo como una ciudad bulliciosa en la que todo funciona a la perfecci\u00f3n, manteniendo el delicado equilibrio de la salud. Ahora, piensa en la esteatohepatitis no alcoh\u00f3lica (NASH) o la esteatohepatitis asociada a la disfunci\u00f3n metab\u00f3lica (MASH) como un\u2026<\/p>","protected":false},"author":3,"featured_media":86610,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[968],"tags":[1104,1270,1202],"class_list":["post-44206","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs-updates","tag-gastroenterology","tag-mash","tag-nash"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/44206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=44206"}],"version-history":[{"count":28,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/44206\/revisions"}],"predecessor-version":[{"id":86631,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/44206\/revisions\/86631"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/86610"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=44206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/categories?post=44206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/tags?post=44206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}